Capital Fund Management (CFM)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Fund Management (CFM)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,700	Closed	-$814K	–	2078
2025 Q4	$814K	Sell	13,700 -51,800	-79%	-$2.82M	﹤0.01%	2090
2025 Q3	$3.55M	Sell	65,500 -13,400	-17%	-$766K	0.01%	1452
2025 Q2	$4.34M	Sell	78,900 -10,100	-11%	-$595K	0.01%	1234
2025 Q1	$6.29M	Sell	89,000 -4,900	-5%	-$330K	0.02%	895
2024 Q4	$6.17M	Buy	+93,900	New	+$6.29M	0.02%	981
2021 Q3	–	Sell	-19,000	Closed	-$1.59M	–	1521
2021 Q2	$1.59M	Buy	19,000 +7,500	+65%	+$595K	0.01%	1026
2021 Q1	$868K	Sell	11,500 -16,200	-58%	-$1.32M	0.01%	1003
2020 Q4	$2.43M	Buy	+27,700	New	+$2.2M	0.02%	717
2016 Q2	–	Sell	-6,900	Closed	-$569K	–	1533
2016 Q1	$569K	Buy	+6,900	New	+$561K	0.01%	1087
2015 Q4	–	Sell	-2,000	Closed	-$211K	–	1543
2015 Q3	$211K	Sell	2,000 -3,400	-63%	-$454K	﹤0.01%	1317
2015 Q2	$739K	Buy	+5,400	New	+$669K	0.01%	924
2015 Q1	–	Sell	-3,000	Closed	-$271K	–	1451
2014 Q4	$271K	Sell	3,000 -5,300	-64%	-$441K	﹤0.01%	1383
2014 Q3	$599K	Buy	8,300 +800	+11%	+$52.6K	0.01%	1099
2014 Q2	$467K	Buy	+7,500	New	+$453K	﹤0.01%	1249
2013 Q4	–	Sell	-27,500	Closed	-$1.99M	–	1652
2013 Q3	$1.99M	Sell	27,500 -56,400	-67%	-$3.75M	0.03%	648
2013 Q2	$4.68M	Buy	+83,900	New	+$5.23M	0.07%	371

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Capital Fund Management (CFM)'s BMRN Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its BioMarin Pharmaceuticals (BMRN) stake by 30% in Q2 2026, buying an estimated $2.98M and bringing the position to 235,421 shares worth $13.5M. The position accounts for 0.06% of the portfolio, ranked #470.

Capital Fund Management (CFM) first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $14.4M in Q3 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Capital Fund Management (CFM) held 235,421 shares of BioMarin Pharmaceuticals worth $13.5M as of Q2 2026.
Capital Fund Management (CFM) bought 54,356 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.98M.
BioMarin Pharmaceuticals made up 0.06% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #470 holding.
Capital Fund Management (CFM) first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Capital Fund Management (CFM)'s BioMarin Pharmaceuticals position peaked at $14.4M in Q3 2015.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.